ArticleFrontiers in neurology
Herbal medicine evaluation for reimbursement-based post-stroke sequelae (HERB-PSS): a retrospective analysis using Korean health insurance claim data, 2020-2024.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Stroke is a leading cause of long-term disability, and many patients experience persistent neurological and functional impairments after the acute phase. The Korean government launched a national pilot reimbursement program for herbal decoctions to improve access to Korean Medicine (KM) rehabilitation and generate real-world evidence on its safety and effectiveness. This study aimed to analyze the utilization patterns, clinical outcomes, and safety of herbal medicine (HM) among patients with post-stroke sequelae participating in the pilot program. Methods: A retrospective analysis was conducted using nationwide health insurance claims data from the Health Insurance Review and Assessment Service (HIRA). Patients diagnosed with sequelae of cerebrovascular disease (KCD codes I69 or U234) who received reimbursed HM prescriptions between November 2020 and April 2024 were included. Demographic characteristics, prescription patterns, and symptom severity were analyzed. Symptom changes between the first and last visits were assessed using the Wilcoxon signed-rank test, and adverse events (AEs) were identified from newly added diagnostic codes after HM treatment. Results: A total of 942 eligible patients were analyzed, with a mean age of 73.2 ± 6.0 years. The majority (57%) initiated KM treatment more than 1 year after stroke onset. The most frequently prescribed formulas were Gamidaebo-tang (23.1%), Mangeum-tang (5.8%), and Gagampalmi-hwan (5.1%). Among 609 patients with paired symptom records, 19.4% showed improvement, 71.9% remained stable, and 8.7% worsened ( Conclusion: This study provides the first nationwide real-world evidence on the use, effectiveness, and safety of HM for post-stroke sequelae under Korea's pilot reimbursement program. Individualized herbal decoctions were widely prescribed and generally well tolerated, showing meaningful symptom stabilization in chronic stroke care. These findings support the feasibility and clinical safety of reimbursed HM and highlight the need for prospective studies to evaluate long-term outcomes, safety, and cost-effectiveness under the expanded second-phase program.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.